Source: Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, was recently featured in several publications highlighting NARCAN® Nasal Spray and Opiant’s development of a treatment for heroin addiction.
In MedCity News, an article titled “In 2016, the opioid epidemic hit home” notes Opiant’s development of NARCAN® Nasal Spray, an intranasal formulation of naloxone designed to reverse opioid overdose. The article provides key insights from CEO Roger Crystal, MD on the expanded use of NARCAN® Nasal Spray in the U.S. and the need to develop new approaches to treat opioid addiction itself.
To read the MedCity News article, please visit the following link:
In Philly.com, an article titled “Scientists say they can make a vaccine against heroin. It’s an uphill battle” discusses the development of heroin vaccines to combat addiction. The article mentions Opiant, which recently licensed a heroin vaccine from the Walter Reed Army Institute of Research (WRAIR) and the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH).
To read the Philly.com article, please visit the following link:
In Scrip Intelligence, an article titled “What Does 2017 Hold for Pharma?” includes expert commentary from leaders across the pharma and biotech spectrum. The article notes Dr. Crystal’s expectation of increasing recognition of addiction as a disease requiring medical treatment and better reimbursement for pharmacotherapy. Additionally, he anticipates increasing access to medical treatment for opioid addiction, as well as additional advances being made into the vaccine space.
To read the Scrip Intelligence article, please visit the following link (available to subscribers only):
In ADVANCE for Nurses, an article titled “The Narcan Debate” spotlights the utility and ease of use of NARCAN® Nasal Spray compared to injectable naloxone in the ongoing battle against opioid overdose. The article also ponders the likelihood that naloxone will continue to serve as the go-to solution for countering overdoses as the opioid epidemic continues to spread.
To read the ADVANCE for Nurses article, please visit the following link:
The articles at the links above are provided for informational purposes only. Opiant is not responsible for the content of the linked articles.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: Corporate Contact: Investor.email@example.com Media Relations: Susan Forman/Laura Radocaj DGI (212) 825-3210